View Past PerformanceAvalyn Pharma バランスシートの健全性財務の健全性 基準チェック /56Avalyn Pharmaの総株主資本は$108.0M 、総負債は$14.8Mで、負債比率は13.7%となります。総資産と総負債はそれぞれ$135.7Mと$27.7Mです。主要情報13.71%負債資本比率US$14.81m負債インタレスト・カバレッジ・レシオn/a現金US$123.13mエクイティUS$107.98m負債合計US$27.69m総資産US$135.66m財務の健全性に関する最新情報更新なしすべての更新を表示Recent updatesライブニュース • Jun 18Avalyn Pharma Stock in Focus as Phase 2b MIST Trial Hits Patient Enrollment Goal EarlyAvalyn Pharma has completed target enrollment of 375 patients in its Phase 2b MIST trial evaluating AP01, an inhaled form of pirfenidone, for progressive pulmonary fibrosis (PPF). The MIST trial reached full enrollment ahead of schedule, indicating strong demand from patients and clinicians for additional treatment options in PPF. Avalyn expects to report topline 12‑month clinical results from the MIST trial in the second half of 2027. Completion of enrollment in this key Phase 2b study marks an important clinical milestone for Avalyn Pharma, as it moves AP01 further along the development path for patients with progressive pulmonary fibrosis. Investors will likely focus on the eventual MIST readout timing and any interim updates, while also considering the usual clinical, regulatory, and funding risks that apply to late-stage drug development.お知らせ • Jun 17Avalyn Pharma Inc. Completes Target Enrollment In Phase 2b MIST Trial Of AP01 For Patients With Progressive Pulmonary FibrosisAvalyn Pharma Inc. completed target enrollment of 375 patients in the Phase 2b MIST clinical trial of AP01 (inhaled pirfenidone) in patients with progressive pulmonary fibrosis (PPF). Additional patients currently in screening remain eligible for randomization and may be enrolled in the trial over the next several weeks. MIST is a global, randomized, double-blinded, placebo-controlled Phase 2b clinical trial evaluating the safety and efficacy of two doses of AP01 in patients with PPF. MIST was designed to enroll 375 patients with PPF, randomized 2:1:2 into three cohorts: AP01 100 mg twice-daily, AP01 50 mg twice-daily, and placebo. The primary endpoint is the change from baseline in lung function, as measured by forced vital capacity (FVC), at 52 weeks. Based on data from the ATLAS Phase 1b trial and ongoing open-label extension study, AP01’s tolerability profile may enable patients to remain on treatment longer. AP01 is an optimized formulation of pirfenidone administered using the PARI eRapid Nebulizer System. AP01 is currently in clinical development for the treatment of progressive pulmonary fibrosis. In the ATLAS Phase 1b study comparing 100 mg twice-daily and 50 mg once-daily doses of AP01, results showed low rates of side effects, including gastrointestinal toxicities and liver enzyme elevations, and suggested a trend toward stability in lung function at the higher dose. AP01 is currently being evaluated in the MIST Phase 2b trial in patients with PPF.ライブニュース • Jun 04Avalyn Pharma Advances Mid-Stage Lung Trials With US$345 Million IPO FundingAvalyn reported first quarter 2026 results and highlighted progress across its inhaled fibrosis programs. The MIST Phase 2b trial of lead candidate AP01 in progressive pulmonary fibrosis is expected to complete enrollment in mid-2026, supported by favorable long-term clinical data. Enrollment is ongoing in the AURA Phase 2 trial of AP02 in idiopathic pulmonary fibrosis, with topline data planned by the end of 2027, and the company recently completed an upsized IPO raising about US$345.0 million to fund operations through 2029. The key takeaway is that Avalyn is now well funded for several years while it advances two mid-stage clinical trials targeting serious lung diseases. Investors should keep in mind that clinical and regulatory outcomes for AP01 and AP02 remain central risks, since Avalyn’s current value is closely tied to trial progress and eventual approval prospects.お知らせ • May 01Avalyn Pharma Inc. has completed an IPO in the amount of $300.000006 million.Avalyn Pharma Inc. has completed an IPO in the amount of $300.000006 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 16,666,667 Price\Range: $18 Discount Per Security: $1.26 Transaction Features: Sponsor Backed Offering財務状況分析短期負債: AVLNの 短期資産 ( $130.0M ) が 短期負債 ( $11.8M ) を超えています。長期負債: AVLNの短期資産 ( $130.0M ) が 長期負債 ( $15.9M ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: AVLN総負債よりも多くの現金を保有しています。負債の削減: AVLNの負債対資本比率が過去 5 年間で減少したかどうかを判断するにはデータが不十分です。貸借対照表キャッシュ・ランウェイ分析過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。安定したキャッシュランウェイ: AVLNは、現在の フリーキャッシュフロー に基づき、1 年以上にわたって十分な キャッシュランウェイ を有しています。キャッシュランウェイの予測: AVLNは、フリー キャッシュ フローが毎年47 % の歴史的率で減少し続ける場合、 1.1年間十分なキャッシュ ランウェイを有しています。健全な企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/23 02:14終値2026/07/23 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Avalyn Pharma Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Gavin Clark-GartnerEvercore ISISeamus FernandezGuggenheim Securities, LLCRoger SongJefferies LLC1 その他のアナリストを表示
ライブニュース • Jun 18Avalyn Pharma Stock in Focus as Phase 2b MIST Trial Hits Patient Enrollment Goal EarlyAvalyn Pharma has completed target enrollment of 375 patients in its Phase 2b MIST trial evaluating AP01, an inhaled form of pirfenidone, for progressive pulmonary fibrosis (PPF). The MIST trial reached full enrollment ahead of schedule, indicating strong demand from patients and clinicians for additional treatment options in PPF. Avalyn expects to report topline 12‑month clinical results from the MIST trial in the second half of 2027. Completion of enrollment in this key Phase 2b study marks an important clinical milestone for Avalyn Pharma, as it moves AP01 further along the development path for patients with progressive pulmonary fibrosis. Investors will likely focus on the eventual MIST readout timing and any interim updates, while also considering the usual clinical, regulatory, and funding risks that apply to late-stage drug development.
お知らせ • Jun 17Avalyn Pharma Inc. Completes Target Enrollment In Phase 2b MIST Trial Of AP01 For Patients With Progressive Pulmonary FibrosisAvalyn Pharma Inc. completed target enrollment of 375 patients in the Phase 2b MIST clinical trial of AP01 (inhaled pirfenidone) in patients with progressive pulmonary fibrosis (PPF). Additional patients currently in screening remain eligible for randomization and may be enrolled in the trial over the next several weeks. MIST is a global, randomized, double-blinded, placebo-controlled Phase 2b clinical trial evaluating the safety and efficacy of two doses of AP01 in patients with PPF. MIST was designed to enroll 375 patients with PPF, randomized 2:1:2 into three cohorts: AP01 100 mg twice-daily, AP01 50 mg twice-daily, and placebo. The primary endpoint is the change from baseline in lung function, as measured by forced vital capacity (FVC), at 52 weeks. Based on data from the ATLAS Phase 1b trial and ongoing open-label extension study, AP01’s tolerability profile may enable patients to remain on treatment longer. AP01 is an optimized formulation of pirfenidone administered using the PARI eRapid Nebulizer System. AP01 is currently in clinical development for the treatment of progressive pulmonary fibrosis. In the ATLAS Phase 1b study comparing 100 mg twice-daily and 50 mg once-daily doses of AP01, results showed low rates of side effects, including gastrointestinal toxicities and liver enzyme elevations, and suggested a trend toward stability in lung function at the higher dose. AP01 is currently being evaluated in the MIST Phase 2b trial in patients with PPF.
ライブニュース • Jun 04Avalyn Pharma Advances Mid-Stage Lung Trials With US$345 Million IPO FundingAvalyn reported first quarter 2026 results and highlighted progress across its inhaled fibrosis programs. The MIST Phase 2b trial of lead candidate AP01 in progressive pulmonary fibrosis is expected to complete enrollment in mid-2026, supported by favorable long-term clinical data. Enrollment is ongoing in the AURA Phase 2 trial of AP02 in idiopathic pulmonary fibrosis, with topline data planned by the end of 2027, and the company recently completed an upsized IPO raising about US$345.0 million to fund operations through 2029. The key takeaway is that Avalyn is now well funded for several years while it advances two mid-stage clinical trials targeting serious lung diseases. Investors should keep in mind that clinical and regulatory outcomes for AP01 and AP02 remain central risks, since Avalyn’s current value is closely tied to trial progress and eventual approval prospects.
お知らせ • May 01Avalyn Pharma Inc. has completed an IPO in the amount of $300.000006 million.Avalyn Pharma Inc. has completed an IPO in the amount of $300.000006 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 16,666,667 Price\Range: $18 Discount Per Security: $1.26 Transaction Features: Sponsor Backed Offering